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Background: Impaired renal function in patients with heart failure is associated with a poor outcome. We analyzed the effect of valsartan as 
add-on to an angiotensin-converting enzyme inhibitor, dual renin-angiotensin-aldosterone system (RAAS) blockade, on the composite endpoint 
of cardiovascular death and heart failure hospitalization in Valsartan in Heart Failure Trial (Val-HeFT) patients according to estimated glomerular 
filtration rate (eGFR) at baseline and by presence of early worsening of renal function (EWRF).
methods: A total of 5,010 clinically stable New York Heart Association class II to IV heart failure patients with reduced ejection fraction enrolled in 
the trial were considered for this post hoc analysis. Renal impairment and EWRF were defined as eGFR<60 mL/min/1.73 m2 at baseline and eGFR 
decrease >20% within 1 month after randomization respectively. Statistical analyses were done using Cox proportional hazards regression model 
and a Wald chi-square test.
results: Baseline eGFR data was available for 5,007 patients. A total of 4,644 (92.7%) patients were receiving angiotensin-converting enzyme 
inhibitors. Renal impairment at baseline was observed in 2,346 (46.8%) patients, while EWRF was seen in 425 (8.6%) patients. Overall, patients 
receiving valsartan showed a significant reduction in composite cardiovascular death and heart failure hospitalization compared with placebo 
(hazard ratio [HR] 0.83 [0.75, 0.92]; p=0.0005). In patients with baseline eGFR<60 mL/min/1.73 m2, dual RAAS conferred significant benefit 
in favor of valsartan on cardiovascular death and heart failure hospitalization as compared to placebo (HR 0.76 [0.66, 0.88]; p=0.0002). Risk of 
cardiovascular death and heart failure hospitalization was significantly higher in patients with EWRF when compared with patients without EWRF 
(HR 1.44 [1.21, 1.71]; p<0.0001). A significant difference between treatment groups was also observed in favor of valsartan (dual RAAS) in EWRF 
patients (HR 0.63 [0.45, 0.89]; p=0.0086).
conclusions: Treatment with dual RAAS blockade in patients with heart failure showed long-term benefits even in patients with EWRF and renal 
dysfunction at baseline.
